Project description
Novel high-sensitivity liquid biopsy in cancer therapy
The analysis of cancer biomarkers during the follow-up of the treatment and in the postoperative period requires high sensitivity. The EU-funded BiopSense project is developing a novel technology that allows very sensitive detection of single-nucleotide polymorphism in the samples, enabling point-of-care screening of liquid biopsies. This diagnostics platform will represent an open system that can accommodate the design of new diagnostic targets. The technology is based on a patented invention and will include features for automated sample preparation and lab-on-chip design. The project objectives include verification of the complete platform components and establishment of the sensitivity and accuracy of the chemistry for evaluation against a competitive mass spectrometry platform.
Objective
Extremely high sensitivity is needed for the detection of cancer biomarkers during the follow-up of the treatment or post-operation period. We have identified a novel technology that enables very sensitive detection of single-nucleotide polymorphism from blood, enabling point-of-care screening of liquid biopsies. Our diagnostics platform will consist of new chemistry and device, and is an open system for designing new diagnostic targets. This will enable customized follow-up of the cancer medication in local hospitals and health care centers. The technology is based on our invention (US patent allowed) further developed in the ERC CoG project, but will have features for automated sample preparation and lab-on-chip design, which need to be verified and combined in the complete platform. For pre-commercialization of the technology, the sensitivity and accuracy of the chemistry will be determined and compared against competing mass spectrometric platform (UltraSEEK by Agena), upgrading our technology from phase TRL 4 to TRL 5. Patent shield of the technology is extended and options for transferring IPR from the University are clarified. Results are presented in investor convention and oncology conferences, and negotiations with investors and out-licensors are started. Three international biotech companies take part in the steering group. The technology allows business potential in device and kit production, but especially in international service business for personalised panel components and medical consultation. The expected price of the device and sample prep will be 30-40% cheaper than that of the closest competitor, but even better it allows flexible design of personalized diagnostic panels. The development for boosting the innovation to market will continue either through a spin-out supported by international investors, together with partnering companies, or through out-licensing.
Fields of science
Programme(s)
Funding Scheme
ERC-POC - Proof of Concept GrantHost institution
40100 Jyvaskyla
Finland